RECRUITINGOBSERVATIONAL

The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping

The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping. An EMBARC2 and EMBARC3 Study

About This Trial

Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine. Primary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment. Secondary Objectives 1. To determine molecular endotypes of stable bronchiectasis 2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations 3. To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine 4. To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials This is an observational cohort study that will aim to identify patient subgroups and link these with meaningful clinical outcomes.

Who May Be Eligible (Plain English)

Who May Qualify: - A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections. - A primary diagnosis of bronchiectasis made by a respiratory physician - At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks. Who Should NOT Join This Trial: - Inability to give willing to sign a consent form - \<18years of age - Patients with active tuberculosis - Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks - Bronchiectasis due to cystic fibrosis Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and/or recurrent respiratory tract infections. * A primary diagnosis of bronchiectasis made by a respiratory physician * At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks. Exclusion Criteria: * Inability to give informed consent * \<18years of age * Patients with active tuberculosis * Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks * Bronchiectasis due to cystic fibrosis

Locations (1)

University of Dundee

Dundee, United Kingdom